We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Electronic Nose Identifies Different Types of Cancer

By LabMedica International staff writers
Posted on 02 Mar 2009
An electronic nose is capable of efficiently and accurately distinguishing between cancer patients and healthy people, and can even detect the location and nature of the tumor.

The development of the electronic nose was based on the knowledge that dogs are capable of detecting cancer in earlier stages by sniffing the patient's breath. More...
Dogs are able to identify molecules created by a tumor that circulate through patient's blood to the lungs, and leave the body when the patient exhales.

Dr. Hossam Haick, of the Russell Berrie Nanotechnology Institute in the Technion's Faculty of Chemical Engineering (Haifa, Israel) headed the team that developed the nose. He conducted a clinical trial together with Professor Abraham Kuten, director of the Rambam Medical Center Oncology Institute (Haifa, Israell). Breath samples were taken from 40 healthy people and 62 cancer patients treated in the hospital. The patients taking part in the trial suffered from lung, breast, colon, prostate, and head and neck cancer. They breathed into bags, which were transferred to the Technion for testing, and the results were compared to details of the patients' diseases according to the hospital's records.

All samples were tested by the electronic nose, and the findings showed that each type of cancer has a particular pattern of characteristic components. The electronic nose was not only able to distinguish between healthy and sick patients, but could also identify different types of cancer with a 92% success rate.

It is foreseen that people being tested will be able to breathe directly into the device. However, Professor Kuten said that the findings must be verified on a larger number of patients.

Related Links:
Technion's Faculty of Chemical Engineering
Rambam Medical Center Oncology Institute



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
POC Immunoassay Analyzer
Procise DX
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.